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Incidence, Predictors, and Significance of Abnormal Cardiac
Enzyme Rise in Patients Treated With Bypass Surgery in
the Arterial Revascularization Therapies Study (ARTS)
Marco A. Costa, MD, PhD; Ronald G. Carere, MD; Samuel V. Lichtenstein, MD;
David P. Foley, MD, MB, MRCPI, PhD; Vincent de Valk, PhD; Wietze Lindenboom, MSc;
Paul C.H. Roose, MD; Theo R. van Geldorp, MD; Carlos Macaya, MD; José L. Castanon, MD;
Francisco Fernandez-Avilèz, MD; Jesús Herreros Gonzáles, MD; Günter Heyer, MD; Felix Unger, MD;
Patrick W. Serruys, MD, PhD; on behalf of ARTS study group
Background—Although it has been suggested that elevation of CK-MB after percutaneous coronary intervention is
associated with adverse clinical outcomes, limited data are available in the setting of coronary bypass grafting. The aim
of the present study was to determine the incidence, predictors, and prognostic significance of CK-MB elevation
following multivessel coronary bypass grafting (CABG).
Methods and Results—The population comprises 496 patients with multivessel coronary disease assigned to CABG in the
Arterial Revascularization Therapies Study (ARTS). CK-MB was prospectively measured at 6, 12, and 18 hours after
the procedure. Thirty-day and 1-year clinical follow-up were performed. Abnormal CK-MB elevation occurred in 61.9%
of the patients. Patients with increased cardiac-enzyme levels after CABG were at increased risk of both death and repeat
myocardial infarction within the first 30 days (P0.001). CK-MB elevation was also independently related to late
adverse outcome (P0.009, OR0.64).
Conclusions—Increased concentrations of CK-MB, which are often dismissed as inconsequential in the setting of
multivessel CABG, appear to occur very frequently and are associated with a significant increase in both repeat
myocardial infarction and death beyond the immediate perioperative period. (Circulation. 2001;104:2689-2693.)
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Myocardial necrosis has classically been detected bymeasurement of the serum creatine kinase (CK) and
specifically the MB isoenzyme (CK-MB), which is more
sensitive and specific.1–4 Elevation of CK-MB following
percutaneous coronary revascularization procedures has been
demonstrated to occur in 6% to 34% of patients.5–10
A recent consensus report has proposed a CK-MB thresh-
old of 3 times the upper limit of normal for percutaneous
revascularization and 5 times for bypass surgery as a marker
for periprocedural myocardial infarction and subsequent in-
creased risk of adverse events.1 This recommendation is
derived mainly from reports on the prognostic significance of
cardiac enzyme elevation after balloon angioplasty or direc-
tional coronary atherectomy (DCA). At present, no definitive
conclusion can be drawn concerning the prognostic signifi-
cance of CK-MB elevation following coronary bypass sur-
gery because of a paucity of data relating to this issue.1,11,12
The Arterial Revascularization Therapies Study (ARTS)
was designed to compare coronary artery bypass grafting
(CABG) and stenting for the treatment of patients with
multivessel coronary disease.13 The aims of the present
investigation were to determine the incidence, predictors, and
prognostic significance of CK-MB elevation following mul-
tivessel CABG.
Methods
ARTS Trial Design
Between April 1997 and June 1998, 1205 patients were randomized
to either stent implantation (n600) or CABG (n605) at 67
participating centers worldwide.13 Only patients who had no previ-
ous angioplasty or CABG procedures were included. The indications
for revascularization were silent ischemia, stable or unstable angina
pectoris, and the presence of at least 2 de novo lesions located in
different major epicardial coronary arteries potentially amenable to
stent implantation. Patients with left main stem stenosis, impaired
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left ventricular function (left ventricular ejection fraction 30%,),
prior cerebrovascular accident (CVA), myocardial infarction within
the week preceding randomization, severe hepatic or renal disease, or
patients who needed concomitant major surgery were not included in
the study. All patients gave written informed consent.
Bypass surgery followed current standard techniques, preferably
using the left internal mammary artery for revascularization of the
left anterior descending coronary artery.13
Data Collection
Angiographic data, including the characteristics of each lesion and
target coronary segment were adjudicated by an independent core
laboratory (Cardialysis BV, Rotterdam). Myocardial infarction (MI)
occurring within 7 days of the procedures was defined as the
appearance of a new Q-wave and cardiac enzymes greater than 5
times the upper limit of normal or a ratio of peak CK-MB/CK
exceeding 0.1. To define a MI after 7 days, either the electrocardio-
graphic or enzymatic criteria sufficed. The Minnesota criteria code
for pathological Q-waves was used, and the EKGs were analyzed by
an independent core laboratory.
Case report forms were verified and compared with each medical
record by the study monitors. Clinical events were adjudicated by an
independent committee.
CK-MB Study Design
All patients enrolled in the ARTS trial and randomized to CABG were
eligible for the present study, a post hoc analysis. Patients were excluded
if they had elevated cardiac enzymes prior to the procedure (n47),
were not treated according to randomization (n26), or if measurements
of cardiac enzymes were not available (n36) in the CABG group.
Blood samples were collected for CK-MB measurements at screening
and at 6, 12, and 18 hours after the procedure. If enzymes were found
to be elevated, CK-MB levels were followed for a longer duration to
determine the actual peak value. These measurements were performed
according to the local laboratory standards. In order to standardize the
analyses at different sites, enzyme levels were expressed based on the
local normal laboratory values. Patients were stratified into 4 categories
of CK-MB levels: normal, 1 to 3, 3 to 5, and more than 5 times the
upper limit of normal in each treatment arm. Because of its low
specificity in detecting myocardial injury, particularly in patients post
CABG, measurements of total CK were not evaluated.
Every itemized clinical event including death, MI, any repeat
revascularization as well as the combined major cardiac (death, MI,
and repeated revascularization) and cerebrovascular events
(MACCE) occurring 24 hours after the procedures were counted
for 30-day and 1-year follow-up analyses. Any event occurring
within 24 hours after the procedure was not counted as an adverse
event in order to avoid the potential confounding influence of the
immediate sequelae of procedural complications.
Statistical Analysis
Statistical analysis was performed using the SAS 6.12 (SAS Institute
Inc). Continuous variables are expressed as meanSD. Binary
outcome variables are reported as frequencies and percentages. In the
30-day analysis,  2 analysis was performed according to Mantel-
Haenszel for comparisons among categorical variables of the sub-
groups. For 1-year follow-up, events were depicted with Kaplan-
Meier curves using the SAS Lifetest procedure, and probability
values were defined by means of log rank analysis. Multivariate
logistic regression models were constructed using baseline charac-
teristics as well as procedure-related factors to identify independent
predictors of CK-MB rise after the procedure. Another multivariate
logistic regression model was constructed to determine whether the
level of cardiac enzyme (CK-MB) after the procedure was an
independent risk-factor for late events. A value of P0.05 was
considered significant.
Results
In the present study, 496 patients treated with CABG were
included. Baseline characteristics are shown in Table 1.
Incidence and Predictors of Postprocedure
CK-MB Release
Overall, abnormal CK-MB elevation occurred in 61.9% of
patients treated with CABG. Figure 1 illustrates the stratifi-
cation of CK-MB elevation.
Figure 1. Frequency of CK-MB elevation after bypass surgery,
according to the prestratified categories (n4) of CK-MB levels.
TABLE 1. Clinical and Procedure-Related Variables
Variables
CABG
(n496)
Clinical characteristics
Age, y 61.5
Male, % 75
Unstable angina, % 36.1
Previous myocardial infarction, % 40.9
Diabetes mellitus, % 16.5
Hypertension, % 45.2
Hypercholesterolemia, % 58.3
Family history, % 42.3
Peripheral vascular disease, % 5.0
Current smoking, % 24.4
Left ventricular ejection fraction, % 60.8
Procedural-related variables
Number of segments diseased* 2.81
Number of segments treated* 2.70.8
Number of distal anastomoses* 2.80.8
Target vessel
Left anterior descending, % 91
Right coronary artery, % 72
Left circumflex, % 72
At least 1 arterial conduit used, % 90
Left internal mammary artery, % 90
Arterial conduit on LAD, % 95
Duration of aorta cross-clamp, min* 44.524
Type of myocardial protection
Crystalloid, % 57
Blood, % 34
Intermittent cross-clamping, % 19
*Numbers are expressed as meanSD.
2690 Circulation November 27, 2001
Factors found to be significant in the univariate analysis
(n22) were entered into the multivariate logistic model.
Several independent risk-factors were found to predict
CK-MB elevation after the procedure (Table 2): use of oral
short-acting nitrates during hospitalization, revascularization
priority (emergency), need for inotropic agents after the
procedure, lesion location in the first circumflex marginal or
intermediate branch, target segments with angulation 90
degrees, duration of aortic cross-clamping, and number of
totally occluded vessels (3 months). Some variables were
found to be protective against CK-MB rise after the proce-
dure: angiographic evidence of thrombus in the target lesion,
the use of angiotensin converting enzyme (ACE) inhibitors
during hospitalization, diabetes mellitus, unstable angina, and
anastomosis in the mid-third of left anterior descending
coronary artery.
Prognostic Significance of Increased CK-MB
Concentration
Table 3 summarizes the incidence of early adverse events
after CABG, according to the stratified levels of CK-MB
elevation. Patients with increased cardiac-enzyme levels after
CABG were at high risk of death as well as repeat MI.
Patients with the highest level (5 times normal) of CK-MB
showed an early mortality rate of 7%. Patients with CK-MB
levels 3 to 5 times normal also had a trend toward an
increased mortality rate as compared with patients with mild
(1 to 3 times normal) CK-MB elevations (P0.065).
All deaths were cardiovascular in origin. One patient with
CK-MB levels 1 to 3 normal died 2 days later after
arrhythmia and cardiac arrest. One patient with CK-MB
elevation 3 to 5 normal developed a bowel infarction and
died after 1 month due to arrhythmias and renal failure. A
second patient with CK-MB levels 3 to 5 normal had a
cardiac arrest 48 to 60 hours postoperatively. Among patients
with CK-MB levels 5 normal, 4 patients died at 2, 3, 18,
and 21 days postoperatively due to postoperative acute
respiratory failure, thrombotic small bowel infarction and
metabolic dysfunction, myocardial infarction, and pulmonary
embolism with cardiogenic shock, respectively.
One-year follow-up data were obtained in all patients.
Patients with postprocedure CK-MB elevation after CABG
were more likely to have adverse events (Figure 2). A strong
relationship between cardiac enzyme levels and each item-
ized clinical event, death, or repeat MI was observed in the
CABG group (Figure 3). Mortality rates were 1.1%, 0.5%,
5.4%, and 10.5%, the incidences of MIs were 1.1%, 1.9%,
2.7%, and 12.3%, CVA occurred in 1.6%, 1.9%, 2.7%, and
1.8%, whereas repeat revascularization occurred in 3.7%,
2.8%, 0%, and 3.5% of patients with CK-MB levels that were
normal,1 to 3, 3 to 5, and5 times normal, respectively.
Predictors of Late Outcome
In order to determine whether elevated CK-MB levels should
be interpreted as an independent marker of worse clinical
outcomes (1-year MACCE) in patients treated with CABG, a
TABLE 2. Independent Predictors of CK-MB Elevation After CABG
Frequency  2 P-value Odds Ratio
Use of oral short-acting nitrates 141/496 14 0.0002 2.13
Angiographic thrombus at screening 19/487 10.6 0.001 0.14
Emergency procedure 13/487 9.2 0.002 5.88
Target lesion in the first marginal
branch
54/496 9.2 0.002 2.38
Need for inotropic agents postprocedure 23/496 8 0.005 3.45
Use of ACE inhibitors 116/496 7.1 0.008 0.56
Diabetes mellitus 82/496 6.6 0.01 0.53
Unstable angina 171/496 6.6 0.01 0.57
Angulation of the target segments 90° 43/496 5.8 0.02 2.08
Duration of aortic cross-clamping, min 5.3 0.02 1.01
Anastomosis in the mid-third of LAD 380/496 4.8 0.03 0.62
Totally occluded vessels, 3 months 16/487 4.9 0.03 2.94
ACE indicates angiotensin converting enzyme, LAD, left anterior descending.
TABLE 3. Incidence of Events up to 30 Days After CABG
CK-MB Level
Normal
(n189)
1–3
(n213)
3–5
(n37)
5
(n57)
Any CK-MB Elevation
(n307) P *
Death, % 0 0.5 5.4 7.0 2.3 0.001
Myocardial infarction, % 1.1 1.4 2.7 12.3 3.9 0.001
CVA, % 1.1 1.4 0 1.8 1.3 NS
Any revascularization, % 0.5 0 0 3.5 0.7 NS
CVA indicates cerebrovascular accident.
*Comparison between the 4 groups.
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multivariate logistic regression was performed. The peak post-
procedural cardiac enzyme level was strongly correlated with
adverse events after CABG (P0.009, OR1.56, 26.8).
Other factors were also found to be predictors of 1-year
MACCE, as follows: emergency procedure (P0.002,
OR10.1, 29.9), age (n13, P0.01, OR1.05, 26.3),
and abnormal monocyte levels (n20, P0.004, OR4.8,
28.3).
Discussion
In the present study, patients treated with CABG experienced
a high incidence of postprocedure CK-MB elevation. CK-MB
elevation 1 to 3 times normal was a frequent finding
(42.9%), and only 38.1% of the patients had normal levels of
CK-MB postoperatively (Figure 1). A small amount of
CK-MB (2% to 4%) may be measurable after skeletal muscle
injury,14 and the manipulation of the heart during operation
may also induce a CK-MB leak.15 A small rise of CK-MB
without irreversible myocardial necrosis has also been
reported.16
Predictors of CK-MB Elevation
A number of factors, including anatomical and procedure-
related variables, independently influenced the level of
CK-MB after CABG. The use of oral short-acting nitrates
was the strongest predictor of abnormal CK-MB elevation
after surgery. This may reflect a deleterious effect of these
agents on myocardial protection during surgery as described
by others.17 Conversely, the use of angiotensin converting
enzyme (ACE) inhibitors had a protective effect on the
myocardium.18 Additional prospective investigations are re-
quired to address this question.
Unstable angina, angiographic evidence of thrombus, and
diabetes mellitus at screening were identified as protective
factors against CK-MB elevation following surgery. Some
previous data may support this paradoxical finding. First,
preconditioning ischemia19,20 may prevent CK-MB elevation
in patients with unstable angina or angiographic thrombus at
screening. Furthermore, in the GUSTO-I trial, diabetic pa-
tients also had lower levels of creatine kinase release com-
pared with nondiabetics.21 These findings may be explained
by a decline in creatine kinase activity related to diabetes as
demonstrated in animal studies.22,23 Finally, intensified med-
ical management in the treatment of these high-risk patients,
either in the time interval between screening and surgery or
during the procedure, cannot be completely ruled out as an
explanation for our findings.
Clinical Implications
The level of CK-MB was shown to be an independent
predictor of clinical events in this population treated with
bypass surgery. Patients with elevated CK-MB levels, partic-
ularly those with levels 5 times normal, were at higher risk
of death or myocardial infarction compared with those with
normal or mild cardiac enzyme elevation. This finding has
not previously been reported in a large prospective multi-
center trial. In fact, the difficulty in determining clinically
relevant myocardial injury during CABG24 has led to the
common belief that cardiac enzymes have limited prognostic
value in this setting.25 A limited number of investigations
have reported the incidence of CK-MB elevation after
CABG,26,27 and virtually no previous study has addressed the
long-term prognostic significance of this biochemical marker.
Based on our findings, increased CK-MB may be consid-
ered as a marker of worse outcome after CABG and patients
with markedly increased levels of CK-MB (5 normal)
should be treated as a high-risk population for subsequent
clinical events (death and/or MI) occurring as early as 30 days
postoperatively. Because a trend toward a higher mortality
rate was also observed in patients with CK-MB elevations3
to 5 normal, these patients may also be considered at
increased risk. Our data justify routine measurement of
cardiac enzymes in patients treated with bypass surgery,
especially in future clinical trials, in order to confirm these
findings.
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Figure 2. Kaplan-Meier curves illustrating the incidence of
MACCE at 1-year follow-up in patients with normal CK-MB lev-
els (dashed gray lines), 1 to 3 times normal (solid gray lines),
3 to 5 times normal (dashed black lines), and 5 times normal
(solid black lines). The P-value refers to the comparison among
the 4 groups.
Figure 3. Kaplan-Meier curves illustrat-
ing the incidence of death and myocar-
dial infarction (MI) at 1-year follow-up in
patients with normal CK-MB levels
(dashed gray lines), 1 to 3 times nor-
mal (solid gray lines), 3 to 5 times nor-
mal (dashed black lines), and 5 times
normal (solid black lines) after bypass
surgery. The P-value refers to the com-
parison among the 4 groups.
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